FindTrial
Sign In

CART cell bridging allogeneic hematopoietic stem cell transplantation for treatment of refractory / relapsed acute myeloid leukemia: non-blind, no- controlled, single center clinical trial

CART cell bridging allogeneic hematopoietic stem cell transplantation for treatment of refractory / relapsed acute myeloid leukemia: non-blind, no- controlled, single center clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16009558
Enrollment
Unknown
Registered
2016-10-23
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory / relapsed acute myeloid leukemia

Interventions

CART cells bridging allogeneic hematopoietic stem cell transplantation:CART cells bridging allogeneic hematopoietic stem cell transplantation

Sponsors

Department of Hematology, Xiniao Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 55 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged under 55 years old; 2. with refractory / relapsed acute myeloid leukemia and no effective treatment modality for selected patients; 3. estimated survival tiem less than 3 months; 4. ECOG=2 scores; 5. No serious systemic organ dysfunction.

Exclusion criteria

Exclusion criteria: 1. Uncontrolled positive infection, HBV or HCV positive; 2. Patients taked part in other cell immunotherapy trials.

Design outcomes

Primary

MeasureTime frame
disease-Free survival of 1 years;—

Secondary

MeasureTime frame
Hematopoietic reconstitution time;ratio of GVHD;Complication of therapy;ratio of relapse;overall survival of 1years;—

Countries

China

Contacts

Public ContactGao Lei

Department of Hematology, Xiniao Hospital

gaolei7765@163.com+86 13228689635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026